Related Experiment Videos
Some practical improvements in the continual reassessment method for phase I studies
S N Goodman1, M L Zahurak, S Piantadosi
1Johns Hopkins University School of Medicine, Division of Biostatistics, Baltimore, MD 21205, USA.
Statistics in Medicine
|June 15, 1995
Summary
Modified Continual Reassessment Method (CRM) designs significantly reduce trial duration and toxicity incidence and severity. These improvements make the Bayesian phase I design more acceptable for clinical drug development.
Area of Science:
- Clinical Trials
- Biostatistics
- Pharmacology
Background:
- The Continual Reassessment Method (CRM) is a Bayesian phase I design for estimating maximum tolerated dose.
- CRM acceptance is limited by trial duration, excessive high-dose experimentation, and toxicity concerns.
Purpose of the Study:
- To evaluate modifications to the CRM design to address its limitations.
- To improve the efficiency and safety of Bayesian phase I clinical trials.
Main Methods:
- A simulation study was conducted using modified CRM protocols.
- Modifications included assigning multiple subjects per dose level and limiting dose increases to one level at a time.
Main Results:
- Modified CRM designs reduced trial duration by 50-67%.
- Toxicity incidence decreased by 20-35%, with reduced severity.
- Accuracy was minimally affected by these modifications.
Conclusions:
- Modified CRM designs effectively address major criticisms of the standard CRM.
- These enhancements increase the acceptability of CRM for clinical investigators and drug development.